Full-Time
Key Account Manager
Blue Grass Region
Updated on 8/23/2026
Secura Bio
51-200 employees
Commercializes oncology therapies and develops COPIKTRA
Compensation Overview
$185k - $226k/yr
Remote in USA
Remote
Overnight travel within the territory and to conferences, training, and sales meetings is required.
Bachelor's, Master's, MBA, PharmD
 Sales & Account Management (1) |
|---|
Get referred to Secura Bio
See people who can refer or advise you
- A bachelor's degree in Life Sciences, Business, Marketing, or a related field is required.
- A minimum of 8 years of successful pharmaceutical or biotechnology sales experience is required.
- A proven track record of achieving or exceeding sales targets is required.
- Experience calling on Medical Oncologists, Hematologists, and/or oncology practices is required.
- Experience launching new products or promoting products in competitive markets is required.
- Ability to understand, retain, and communicate complex clinical, efficacy, and safety data is required.
- A strong grasp of oncology and hematology disease states and treatment paradigms is required.
- Capability to engage in scientific discussions with highly trained medical professionals is required.
- Strategic territory planning and business plan development experience is required.
- Strong analytical skills to assess territory opportunities and track performance metrics are required.
- A thorough understanding of pharmaceutical industry regulations, including FDA requirements, the PhRMA Code, and OIG guidelines, is required.
- Commitment to ethical selling practices and promoting products within approved indications is required.
- Excellent presentation and public speaking skills are required.
- Ability to work effectively with cross-functional teams, including Medical Affairs, Market Access, and Marketing, is required.
- Promote Copiktra and other approved drugs in a fair and balanced manner consistent with company policies and approved indications.
- Improve customer awareness and on-label sales of Copiktra within the assigned territory.
- Educate appropriate health care providers on the on-label use of Copiktra by delivering clinical, efficacy, and safety messaging using company-approved promotional materials.
- Develop and execute comprehensive territory business plans aligned with corporate strategic objectives.
- Conduct monthly business reviews to analyze progress, identify opportunities and risks, and implement data-driven adjustments.
- Achieve on-label sales growth consistent with the business plan and company policies.
- Monitor operating costs and manage the territory budget.
- Identify key practice decision-makers and conduct promotional presentations, informational in-services, and educational programs for targeted customers.
- Support the company's commercial presence at appropriate key medical congresses in the territory.
- Engage Medical Science Liaisons or designated Medical Affairs contacts for appropriate follow-up on customer questions.
- Comply with company policies and applicable laws.
- Travel overnight within the territory and to conferences, training, and sales meetings.
- An advanced degree, such as an MBA, MS, PharmD, or related discipline, is preferred.
Secura Bio is an integrated biopharmaceutical company focused on bringing oncology therapies to patients. Its main product is COPIKTRA (duvelisib), an oral PI3K inhibitor used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also running a Phase 3 study of COPIKTRA for relapsed or refractory nodal T-follicular helper cell lymphoma. Secura Bio’s approach centers on acquiring, developing, and commercializing approved and late-stage oncology assets, with headquarters in Las Vegas and a European office in Dublin. In simple terms, the company buys or develops cancer drugs and then brings them to doctors and patients who need them. Its goal is to close the gap between available oncology therapies and the patients who can benefit from them.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$55M
Headquarters
Mesa, Arizona
Founded
2019
Get referred to Secura Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- PRIMO's April 27, 2026 JCO publication validated duvelisib in relapsed peripheral T-cell lymphoma.
- Secura Bio said November 2025 U.S. COPIKTRA sales grew over 30% year over year.
- TERZO randomized 35 of 124 patients by December 22, 2025, supporting early-2027 readout.
What critics are saying
- COPIKTRA is a single-product business; any setback in TERZO cripples 2027 growth.
- The FDA label limits COPIKTRA to third-line CLL/SLL because of treatment-related mortality.
- Europe withdrew Copiktra on February 16, 2026, eliminating an entire commercial region.
What makes Secura Bio unique
- COPIKTRA is the first U.S.-approved dual PI3K-delta and PI3K-gamma inhibitor.
- Secura Bio buys late-stage oncology assets and commercializes them globally from 2019 onward.
- TERZO and PRIMO give Secura Bio a rare commercial-plus-development lymphoma platform.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -3%Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer. February 11, 2026 07:00 ET | Source: Secura Bio BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) - Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company's strategic goals, while continuing to lead Secura Bio's financial operations and strategic planning. "Will has been instrumental in shaping our financial foundation and driving operational rigor with his extensive knowledge of the biopharmaceutical industry and deep understanding of our business," said Chip Romp, Chief Executive Officer of Secura Bio. "Expanding Will's role to include additional responsibilities as COO is a natural move for us given his exceptional leadership. Will's strategic perspective and insights will be essential to Secura Bio as we continue to embark on our bold vision to change outcomes in human health by expanding the potential of oncology medicines." Mr. Brown added, "Secura Bio is well positioned to scale and grow, and I'm excited by our long-term prospects to commercialize transformative therapies for patients while building substantial value for shareholders. I'm honored to work with such an incredible team and am inspired by the shared commitment and focus brought to work each day as we focus on our strategic initiatives to build a world-class biopharmaceutical company." Mr. Brown joined Secura Bio as Chief Financial Officer in 2024. Prior to Secura Bio, Mr. Brown served as Chief Financial Officer and Interim Chief Executive Officer at ObsEva SA, where he successfully led the company through a restructuring that generated a strategic disposition of over $100 million. Prior to ObsEva SA, Mr. Brown served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company, guiding them through more than $300 million in new equity issuances and a strategic acquisition. Prior to his pharmaceutical industry roles, Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown earned both his MBA and BS in accounting from Auburn University Montgomery. About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. For more information on Secura Bio, please visit https://www.securabio.com/. Investor & Media Contact Will Brown CFO & COO Phone: 334-313-2319 [email protected] Media Contact Kit Rodophele Ten Bridge Communications Phone: 617-999-9620 [email protected]
Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer. BERKELEY HEIGHTS, NJ, February 11, 2026 (GLOBE NEWSWIRE) - Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company's strategic goals, while continuing to lead Secura Bio's financial operations and strategic planning. "Will has been instrumental in shaping our financial foundation and driving operational rigor with his extensive knowledge of the biopharmaceutical industry and deep understanding of our business," said Chip Romp, Chief Executive Officer of Secura Bio. "Expanding Will's role to include additional responsibilities as COO is a natural move for us given his exceptional leadership. Will's strategic perspective and insights will be essential to Secura Bio as we continue to embark on our bold vision to change outcomes in human health by expanding the potential of oncology medicines." Mr. Brown added, "Secura Bio is well positioned to scale and grow, and I'm excited by our long-term prospects to commercialize transformative therapies for patients while building substantial value for shareholders. I'm honored to work with such an incredible team and am inspired by the shared commitment and focus brought to work each day as we focus on our strategic initiatives to build a world-class biopharmaceutical company." Mr. Brown joined Secura Bio as Chief Financial Officer in 2024. Prior to Secura Bio, Mr. Brown served as Chief Financial Officer and Interim Chief Executive Officer at ObsEva SA, where he successfully led the company through a restructuring that generated a strategic disposition of over $100 million. Prior to ObsEva SA, Mr. Brown served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company, guiding them through more than $300 million in new equity issuances and a strategic acquisition. Prior to his pharmaceutical industry roles, Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown earned both his MBA and BS in accounting from Auburn University Montgomery. About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. For more information on Secura Bio, please visit https://www.securabio.com/. Investor & Media Contact Will Brown CFO & COO Phone: 334-313-2319 [email protected] Media Contact Kit Rodophele Ten Bridge Communications Phone: 617-999-9620 [email protected]
SUMMERLIN, Nev., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, is pleased to announce the appointment of Dr. Patrick Vink, a global biopharmaceutical executive experienced in development, marketing, and commercialization, as Chairman of its Board of Directors.Dr. Vink brings over 35 years of industry experience and currently serves as Chairman and Board member of several public and private biopharma companies, both in the U.S. and in Europe, including F2G Ltd and Essential Pharma
Its product, COPIKTRA(R), is currently approved for the treatment of multiple B-cell malignancies and is also being developed for the treatment of peripheral T-cell lymphoma, for which it has received Fast Track status in the United States and is being investigated in combination with other agents through investigator-sponsored studies.
Secura Bio acquired FARYDAK in March 2019.